Annalisa Michielon

Annalisa Michielon

Auto-generated profile, based on publicly available information

Annalisa Michielon

Food and Drug Department, University of Parma, Parma, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2023 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
PDF file
Annalisa BiancheraAnnalisa Bianchera
Annalisa Bianchera
VVViviana Vilardo
Viviana Vilardo
RGRoberta Giaccari
Roberta Giaccari
AMAnnalisa Michielon
Annalisa Michielon
GBGianluca Bazzoli
Gianluca Bazzoli
Ruggero BettiniRuggero Bettini
Ruggero Bettini
The nebulization of alpha-1 antitrypsin (AAT) for its administration to the lung could be an interesting alternative to parenteral infusion for patients suffering from AAT genetic deficiency (AATD). In the case of protein therapeutics, the effect of the nebulization mode and rate on protein conformation and activity must be carefully considered. In this paper two types of nebulizers, i.e., a jet and a mesh vibrating system, were used to nebulize a commercial preparation of AAT for infusion and compared. The aerosolization performance, in terms of mass distribution, respirable fraction, and drug delivery efficiency, as well as the activity and aggregation state of AAT upon in vitro nebulization were investigated. The two nebulizers demonstrated equivalent aerosolization performances, but the mesh nebulizer provided a higher efficiency in the delivery of the dose. The activity of the protein was acceptably preserved by both nebulizers and no aggregation or changes in its conformation were identified. This suggests that nebulization of AAT represents a suitable administration strategy ready to be translated to the clinical practice for delivering the protein directly to the lungs in AATD patients, either as a support therapy to parenteral administration or for subjects with a precocious diagnosis, to prevent the onset of pulmonary symptoms. Graphical Abstract